论文部分内容阅读
原发性肝癌是一种常见又难治的恶性肿瘤。2000年全球因肝癌死亡者高达54．86万人;全球新发肝癌病例中约53%发生在我国,中国肝癌死亡率1992年20．4/10万人至2004年上升达54．7/10万人,肝癌也是癌症导致死亡的第2位原因。它的高发病率、高死亡率、高年增长率构成世界之最,严重危害着人民的健康和生命,目前仍缺乏一种特效的治疗方法,人们期待着有价值的治疗方案,对这些病人的治疗研究仍是一项重要工程,具有重大的社会意义。
Primary liver cancer is a common and refractory malignancy. In 2000, 548,600 people died of liver cancer in the world; about 53% of the new cases of liver cancer in the world occurred in China. The mortality rate of liver cancer in China increased from 20.4 / 100 in 1992 to 54.7 / 10 in 2004 Million, liver cancer is the second leading cause of death from cancer. Its high morbidity, high mortality and high growth rate constitute the highest in the world, which seriously endanger people’s health and life. Currently, there is still a lack of effective treatments and people are looking forward to valuable treatment programs for these patients The treatment research is still an important project with great social significance.